Loading...
SPPI logo

Spectrum Pharmaceuticals, Inc.NasdaqCM:SPPI Stock Report

Market Cap US$209.9m
Share Price
n/a
n/a
0
1Y17.0%
7D5.3%
1D
Portfolio Value
​
View

Spectrum Pharmaceuticals, Inc.

NasdaqCM:SPPI Stock Report

Market Cap: US$209.9m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Spectrum Pharmaceuticals (SPPI) Stock Overview

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. More details

SPPI fundamental analysis
Snowflake Score
Valuation6/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Trading at 82.9% below our estimate of its fair value

Earnings are forecast to grow 67.27% per year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 22.3%

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been diluted in the past year


SPPI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Spectrum Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Spectrum Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.03
52 Week HighUS$1.57
52 Week LowUS$0.32
Beta2.14
1 Month Change4.54%
3 Month Change-1.90%
1 Year Change17.05%
3 Year Change-71.39%
5 Year Change-95.10%
Change since IPO-99.25%

Recent News & Updates

Recent updates

Analysis Article • May 14

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Shareholders in Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) may be thrilled to learn that the analysts have just...
Analysis Article • May 12

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) investors will be delighted, with the company turning in some strong...
Seeking Alpha • Sep 20

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

US FDA scientists are concerned about the data Spectrum Pharmaceuticals (NASDAQ:SPPI) has provided to support its drug poziotinib for non-small cell lung cancer ahead of an advisory committee meeting on Thursday. Shares are down 28% in Tuesday morning trading. In a briefing document, the FDA scientists state the data provided shows a low overall response rate (ORR) with minimal duration of response (DOR). ORR was 28% while median DOR was 5.1 months. In addition, they say the safety profile is poor in that at the proposed dosage, 57% of patients experienced dose reductions and 85% of patients had grade 3-4 adverse events. Also, the FDA team faults Spectrum (SPPI) for what it calls inadequate dosage optimization since the company has proposed two different doses for accelerated approval and the planned confirmatory trial. "Confirmation of benefit will be significantly delayed given that confirmatory trial has not begun enrolling patients." Poziotinib is an oral tyrosine kinase inhibitor that inhibits the activity of epidermal growth factor receptor (EGFR [HER1], HER2, and HER4) kinases. Seeking Alpha's Quant Rating views Spectrum (SPPI) as a hold.
Analysis Article • Sep 16

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Sep 09

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Spectrum Pharmaceuticals (NASDAQ:SPPI) stock jumped 10.4% afterhours on Friday after the U.S. Food and Drug Administration approved its Rolvedon injection. The injection is used to treat chemotherapy-induced neutropenia (abnormally low count of a type of neutrophils). SPPI said the FDA's nod marks the first novel long-acting GCSF (LA-GCSF) product approval in over 20 years. The company plans to commercially launch the injection in Q4. Shares of SPPI have fallen 18.2% YTD.
Seeking Alpha • Aug 21

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

We are circling back on a small biopharma named Spectrum Pharmaceuticals for the first time in a year and a half today. Spectrum has turned into a soap opera since then with two departures from the C-Suite, a CRL, and a significant workforce reduction. However, the company still is pushing two compounds towards potential FDA approval this year. An investment analysis follows in the paragraphs below. "Even as a solid rock is unshaken by the wind, so are the wise unshaken by praise or blame."― Dhammapada We last posted an article on Spectrum Pharmaceuticals (SPPI) back in March of 2021. At that time, we declined any investment recommendation on the shares but did promise to circle back on this name as its story developed. The company reported second-quarter results earlier this month and I have gotten a question or two from Seeking Alpha followers recently. Therefore, we will revisit this small biopharma company via the analysis below. Seeking Alpha Company Overview: Spectrum Pharmaceuticals focuses on developing and commercializing novel and targeted drug products with a primary focus in oncology. The company is headquartered just outside of Las Vegas. The stock currently trades around $1.25 a share and sports an approximate market capitalization of $250 million. Recent Developments: The company has been a non-stop soap opera since we last looked in on it. Its primary asset is ROLONTIS (eflapegrastim). Spectrum had submitted a marketing application on it for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs. This candidate has had a rocky ride, to say the least, towards FDA approval. First, the inspection of the manufacturing facility where ROLONTIS was to be made in South Korea by partner Hanmi was delayed thanks to the pandemic. March Company Presentation Then in August of 2021, the FDA slapped Spectrum's Biologics License Application or BLA with a Complete Response Letter or CRL. The CRL cited deficiencies related to manufacturing and indicated that a re-inspection will be necessary. Then in December of last year, the company announced its CEO was retiring which was followed by resignation of its CFO in February of this year. In between those management losses, Spectrum announced a restructuring that resulted in approximately 30% of its workforce being let go. The company also halted development of early-stage drug candidates to focus solely on pushing poziotinib and ROLONTIS across the finish line. These measures were projected to reduce annual cash burn by 20% to 25% and push the company's 'cash runway' into 2023. The company did resubmit its BLA for ROLONTIS in April and the FDA is scheduled to make a decision on its application on September 9th. January 2021 Company Presentation The FDA completed re-inspection of the manufacturing facility for ROLONTIS in August. Chemo-induced neutropenia impacts just over one million individuals in the United States. ROLONTIS would be the first drug in its class approved for this indication since Neulasta got the green light from the FDA in 2002. March Company Presentation March Company Presentation The approval path for poziotinib has been much smoother to this point. The compound is targeting patients with previously treated, locally advanced or metastatic non-small cell lung cancer, harboring HER2 exon 20 insertion mutations. This drug candidate is an orally administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations. Poziotinib has fast track designation and is on an accelerated approval pathway for this indication. The NDA was submitted some ago has a PDUFA date of November 24th of this year. It is important to note Poziotinib has a much smaller potential market than ROLONTIS and the company will have to demonstrate the compound has an overall risk benefit and clinical relevance based on its 'ZENITH' study to the FDA to garner approval. A randomized confirmatory trial is currently ongoing. A critical phase 2 trial in 2nd line NSCLC patients with EGFR exon 20 mutations around Poziotinib did not meet its primary endpoint of ORR in one of its cohorts early in 2020. Analyst Commentary & Balance Sheet: Since second quarter results posted, B. Riley Financial ($4 price target), H.C. Wainwright ($10 price target) and JMP Securities ($4 price target) have all reiterated Buy ratings on SPPI.
Seeking Alpha • Aug 10

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Spectrum Pharmaceuticals (NASDAQ:SPPI) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.10 (+60.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 2 years, SPPI has beaten EPS estimates 38% of the time and has beaten revenue estimates 13% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward.
Analysis Article • Jun 04

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 25

Spectrum Pharmaceuticals: Some Last Words

A spate of bad luck has destroyed SPPI stock. CEO and CFO have both resigned. Even if, somehow, ROLONTIS gets approved, they don't have the cash to commercialize.
Analysis Article • Oct 05

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 12

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

SPPI received a surprise CRL for rolontis. This could be resolved before the year is out, but there is no real clarity. The company does have enough cash to last it for a year or more.
Seeking Alpha • Jul 29

Spectrum's Big Approval: Any Day Now

The FDA completed the inspection of Hanmi's Korean facility almost a month ago. Approval should happen any day now. Rolontis is targeting a $3bn+ market.
Analysis Article • May 31

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 12

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 21

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

A look at the shareholders of Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) can tell us which group is most powerful...

Shareholder Returns

SPPIUS BiotechsUS Market
7D5.3%-1.6%-0.8%
1Y17.0%34.4%27.1%

Return vs Industry: SPPI exceeded the US Biotechs industry which returned -4.2% over the past year.

Return vs Market: SPPI exceeded the US Market which returned 14.1% over the past year.

Price Volatility

Is SPPI's price volatile compared to industry and market?
SPPI volatility
SPPI Average Weekly Movement7.2%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Stable Share Price: SPPI's share price has been volatile over the past 3 months.

Volatility Over Time: SPPI's weekly volatility has decreased from 15% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
198786Tom Rigawww.sppirx.com

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations.

Spectrum Pharmaceuticals, Inc. Fundamentals Summary

How do Spectrum Pharmaceuticals's earnings and revenue compare to its market cap?
SPPI fundamental statistics
Market capUS$209.89m
Earnings (TTM)-US$67.71m
Revenue (TTM)US$25.73m
8.2x
P/S Ratio
-3.1x
P/E Ratio

Is SPPI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPPI income statement (TTM)
RevenueUS$25.73m
Cost of RevenueUS$2.86m
Gross ProfitUS$22.87m
Other ExpensesUS$90.58m
Earnings-US$67.71m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.33
Gross Margin88.90%
Net Profit Margin-263.16%
Debt/Equity Ratio107.6%

How did SPPI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/02 19:42
End of Day Share Price 2023/07/31 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Spectrum Pharmaceuticals, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David BuckB. Riley Securities, Inc.
Alethia YoungCantor Fitzgerald & Co.
Reni BenjaminCitizens JMP Securities, LLC